Watchlist Price Alert

scPharmaceuticals Inc. (SCPH)

NASDAQ: SCPH · Real-Time Price · USD

4.11

-0.01 (-0.24%)

At close: Jun 05, 2025, 3:59 PM

4.00

-2.68%

After-hours: Jun 05, 2025, 06:55 PM EDT

-0.24% (1D)

Bid	3.65
Market Cap	216.98M
Revenue (ttm)	41.98M
Net Income (ttm)	-90.78M
EPS (ttm)	-1.92
PE Ratio (ttm)	-2.14
Forward PE	-14.33
Analyst	Buy

Ask	4.36
Volume	595,219
Avg. Volume (20D)	478,441
Open	4.10
Previous Close	4.12
Day's Range	4.08 - 4.29
52-Week Range	1.94 - 5.65
Beta	0.36

About SCPH

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SCPH

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SCPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

+28.57%

scPharmaceuticals shares are trading higher after ... Unlock content with Pro Subscription

3 months ago

-1.89%

scPharmaceuticals shares are trading higher after the company announced FDA approval for a supplemental new drug application expanding the FUROSCIX indication to include the treatment of edema in patients with chronic kidney disease.

News

2 weeks ago · seekingalpha.com

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

Shares of scPharmaceuticals have lost 37% over the past 3 years and are down 11% in 2025. Furoscix's subcutaneous administration offers the potential to keep heart failure patients at home longer and ...

3 weeks ago · seekingalpha.com

scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants William Thorpe - Investor Relations John Tucker - Chief Executive Officer Steve Pars...

3 weeks ago · zacks.com

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.36 per share a year ago.

2 months ago · seekingalpha.com

scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Par...

2 months ago · zacks.com

ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.35 per share a year ago.

3 months ago · zacks.com

ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?

ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.